Literature DB >> 24777106

Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Thomas W North1, Andradi Villalobos2, Selwyn J Hurwitz3, Jesse D Deere4, Joanne Higgins4, Payel Chatterjee3, Sijia Tao3, Robert C Kauffman4, Paul A Luciw4, James J Kohler3, Raymond F Schinazi5.   

Abstract

Using an established nonhuman primate model, rhesus macaques were infected intravenously with a chimeric simian immunodeficiency virus (SIV) consisting of SIVmac239 with the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase from clone HXBc2 (RT-SHIV). The impacts of two enhanced (four- and five-drug) highly active antiretroviral therapies (HAART) on early viral decay and rebound were determined. The four-drug combination consisted of an integrase inhibitor, L-870-812 (L-812), together with a three-drug regimen comprising emtricitabine [(-)-FTC], tenofovir (TFV), and efavirenz (EFV). The five-drug combination consisted of one analog for each of the four DNA precursors {using TFV, (-)-FTC, (-)-β-D-(2R,4R)-1,3-dioxolane-2,6-diaminopurine (amdoxovir [DAPD]), and zidovudine (AZT)}, together with EFV. A cohort treated with a three-drug combination of (-)-FTC, TFV, and EFV served as treated controls. Daily administration of a three-, four-, or five-drug combination of antiretroviral agents was initiated at week 6 or 8 after inoculation and continued up to week 50, followed by a rebound period. Plasma samples were collected routinely, and drug levels were monitored using liquid chromatography-tandem mass spectrometry (LC-MS-MS). Viral loads were monitored with a standard TaqMan quantitative reverse transcriptase PCR (qRT-PCR) assay. Comprehensive analyses of replication dynamics were performed. RT-SHIV infection in rhesus macaques produced typical viral infection kinetics, with untreated controls establishing persistent viral loads of >10(4) copies of RNA/ml. RT-SHIV loads at the start of treatment (V0) were similar in all treated cohorts (P > 0.5). All antiretroviral drug levels were measureable in plasma. The four-drug and five-drug combination regimens (enhanced HAART) improved suppression of the viral load (within 1 week; P < 0.01) and had overall greater potency (P < 0.02) than the three-drug regimen (HAART). Moreover, rebound viremia occurred rapidly following cessation of any treatment. The enhanced HAART (four- or five-drug combination) showed significant improvement in viral suppression compared to the three-drug combination, but no combination was sufficient to eliminate viral reservoirs.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24777106      PMCID: PMC4068512          DOI: 10.1128/AAC.02522-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

Review 1.  Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

Authors:  Natasha Press; Mark W Tyndall; Evan Wood; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

2.  Susceptibilities of simian immunodeficiency virus to protease inhibitors.

Authors:  Angelica C Giuffre; Joanne Higgins; Robert W Buckheit; Thomas W North
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Kelly Soderberg; Lynn Denekamp; Sarah Nikiforow; Karen Sautter; Ronald C Desrosiers; Louis Alexander
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 4.  Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

Authors:  Eliza H Humphreys; Larry W Chang; Jamal Harris
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

5.  Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA.

Authors:  C M Leutenegger; J Higgins; T B Matthews; A F Tarantal; P A Luciw; N C Pedersen; T W North
Journal:  AIDS Res Hum Retroviruses       Date:  2001-02-10       Impact factor: 2.205

6.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

7.  Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Authors:  Daria J Hazuda; Steven D Young; James P Guare; Neville J Anthony; Robert P Gomez; John S Wai; Joseph P Vacca; Larry Handt; Sherri L Motzel; Hilton J Klein; Geethanjali Dornadula; Robert M Danovich; Marc V Witmer; Keith A A Wilson; Lynda Tussey; William A Schleif; Lori S Gabryelski; Lixia Jin; Michael D Miller; Danilo R Casimiro; Emilio A Emini; John W Shiver
Journal:  Science       Date:  2004-07-08       Impact factor: 47.728

Review 8.  Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Prem L Sharma; Viktoria Nurpeisov; Brenda Hernandez-Santiago; Thierry Beltran; Raymond F Schinazi
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

9.  Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model.

Authors:  Christopher Kline; Jean Ndjomou; Tamera Franks; Rebecca Kiser; Vicky Coalter; Jeremy Smedley; Michael Piatak; John W Mellors; Jeffrey D Lifson; Zandrea Ambrose
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

Review 10.  Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.

Authors:  Aftab A Ansari; Ann E Mayne; Nattawat Onlamoon; Kovit Pattanapanyasat; Kazuyasu Mori; Francois Villinger
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

View more
  4 in total

1.  Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells.

Authors:  Joseph A Hollenbaugh; Susan M Schader; Raymond F Schinazi; Baek Kim
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

2.  Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.

Authors:  Charles W Dobard; Andrew Taylor; Sunita Sharma; Peter L Anderson; Lane R Bushman; Dinh Chuong; Chou-Pong Pau; Debra Hanson; Lin Wang; J Gerardo Garcia-Lerma; Ian McGowan; Lisa Rohan; Walid Heneine
Journal:  J Infect Dis       Date:  2015-06-12       Impact factor: 5.226

Review 3.  Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.

Authors:  Paul W Denton; Ole S Søgaard; Martin Tolstrup
Journal:  J Transl Med       Date:  2016-02-09       Impact factor: 5.531

4.  Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.

Authors:  Pengfei Wang; Mili R Gajjar; Jian Yu; Neal N Padte; Agegnehu Gettie; James L Blanchard; Kasi Russell-Lodrigue; Laura E Liao; Alan S Perelson; Yaoxing Huang; David D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-14       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.